Prevention and Treatment of Central Nervous System Involvement by Non-Hodgkin's Lymphoma: A Review of the Literature

ABSTRACT

Direct invasion of the central nervous system (CNS) occurs in 5% of all patients with non-Hodgkin's lymphoma, either at the time of presentation, as a solitary site of relapse, or during the course of progressive disease. Over the last several years, several studies, mostly retrospective, have analyzed risk factors associated with this complication as well as various methods to both treat and prevent it. A systematic review of the literature reveals that although a profile of a patient at particularly high risk for developing disease can be identified, treatments are for the most part ineffective at improving survival in patients with CNS lymphoma, and there is no high-quality evidence that prophylaxis prevents its occurrence. A randomized controlled trial to assess the value of prophylaxis in this disease is warranted, and suggestions for how such a trial might be designed are included in this review.

Leptomeningeal lymphoma - CNS prophylaxis - intraventricular

REFERENCES

• 1 Recht L, Mrugala M. Neurologic complications of hematologic neoplasms.  Neurol Clin. 2003;  21 87-105
• 2 Mrugala M, Recht L. Neurological complications of Hodgkin's disease. In: Batchelor T, ed. Lymphoma of the Nervous System. Boston; Butterworth-Heinemann 2004: 123-132
• 3 Rappaport H. Tumors of the hematopoietic system. Atlas of Tumor Pathology, Series I, Section III, Fascicle 8. Washington, DC: Armed Forces Institute of Pathology;. 1966
• 4 Tomita N, Kodama F, Kanamori H, Motomura S, Ishigatsubo Y. Prophylactic intrathecal methotrexate and hydrocortisone reduces central nervous system recurrence and improves survival in aggressive non-Hodgkin lymphoma.  Cancer. 2002;  95 576-580
• 5 Lennert K, Feller A C. Histopathology of Non-Hodgkin's Lymphoma (according to the up-dated Kiel classification). Berlin: Springer;. 1992
• 6 Project N H. National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas: summary and description of a working formulation for clinical usage.  Cancer. 1982;  49 2112-2135
• 7 Harris N L, Jaffee E S, Stein H et al.. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group.  Blood. 1994;  84 1361-1392
• 8 Jaffee E S, Harris N L, Stein H et al.. World Health Organization Classification of Tumours of the Haematopoietic and Lymphoid Tissues. Lyon; IARC Press 2001
• 9 Hiddemann W, Longo D L, Coiffier B et al.. Lymphoma classification-The gap between biology and clinical management is closing.  Blood. 1996;  88 4085-4089
• 10 Hollender A, Kvaloy S, Nome O, Skovlund E, Lote K, Holte E. Central nervous system involvement following diagnosis of non-Hodgkin's lymphoma: a risk model.  Ann Oncol. 2002;  13 1099-1107
• 11 Bos G MJ, van Putten W L, van der Holt B et al.. For which patients with aggressive non-Hodgkin's lymphoma is prophylaxis for central nervous system disease mandatory?.  Ann Oncol. 1998;  9 191-194
• 12 Zinzani P L, Magagnoli M, Frezza G et al.. Isolated central nervous system relapse in aggressive non-Hodgkin's lymphoma: the Bologna experience.  Leuk Lymphoma. 1999;  32 571-576
• 13 Haioun C, Besson C, Lepage E et al.. Incidence and risk factors of central nervous system relapse in histologically aggressive non-Hodgkin's lymphoma uniformly treated and receiving intrathecal central nervous system prophylaxis: a GELA study on 974 patients.  Ann Oncol. 2000;  11 685-690
• 14 Tomita N, Kodama F, Sakai R et al.. Predictive factors for central nervous system involvement in non-Hodgkin's lymphoma: significance of a very high serum LDH concentration.  Leuk Lymphoma. 2000;  38 335-343
• 15 Bollen E L, Brouwer R E, Hamers S et al.. Central nervous system relapse in non-Hodgkin's lymphoma.  Arch Neurol. 1997;  54 854-859
• 16 van Biesen K, Ha C S, Murphy S et al.. Risk factors, treatment, and outcome of central nervous system recurrence in adults with intermediate-grade and immunoblastic lymphoma.  Blood. 1998;  91 1178-1184
• 17 Ersbøll J, Schultz H B, Thomsen B LR, Keiding N, Nissen N I. Meningeal involvement by non-Hodgkin's lymphoma: symptoms, incidence, risk factors and treatment.  Scand J Haematol. 1985;  35 487-496
• 18 Hoerni-Simon G, Suchaud J P, Eghbali H, Coindre J M, Hoerni B. Secondary involvement of the central nervous system in malignant non-Hodgkin's lymphoma.  Oncology. 1987;  44 98-101
• 19 Liang R, Chiu E, Loke S L. Secondary central nervous system involvement by non-Hodgkin's lymphoma: the risk factors.  Hematol Oncol. 1990;  8 141-145
• 20 Bashir R M, Bierman P J, Vose J M, Weisenburger D D, Armitage J O. Central nervous system involvement in patients with diffuse aggressive non-Hodgkin's lymphoma.  Am J Clin Oncol. 1991;  14 478-482
• 21 Keldsen N, Michalski W, Bentzen S, Hansen K, Thorling K. Risk factors for central nervous system involvement in non-Hodgkin's lymphoma.  Acta Oncol. 1996;  35 703-708
• 22 Wolf M M, Cooper I A, Olver I N et al.. Non-Hodgkin's lymphoma involving the central nervous system.  Aust N Z J Med. 1985;  15 16-20
• 23 Recht L, Straus D J, Cirrincione C et al.. Central nervous system metastases from non-Hodgkin's lymphoma: treatment and prophylaxis.  Am J Med. 1988;  84 425-433
• 24 Bunn P A, Schein P S, Banks P M et al.. Central nervous system complications in patients with diffuse histiocytic and undifferentiated lymphoma: leukemia revisited.  Blood. 1976;  47 3-10
• 25 Mackintosh F R, Colby T V, Podolsky W J et al.. Central nervous system involvement in non-Hodgkin's lymphoma: an analysis of 105 cases.  Cancer. 1982;  49 586-595
• 26 Cairncross J G, Posner J B. Neurological complications of malignant lymphoma. In: Vinken PJ, Bruyn GW, eds. Handbook of Clinical Neurology. Amsterdam: North Holland Publishing;. 1980: 27-62
• 27 Lokich J, Galbo C. Leptomeningeal lymphoma: perspectives on management.  Cancer Treat Rev. 1981;  8 103-110
• 28 Griffin J W, Thompson R W, Mitchinson M J et al.. Lymphomatous leptomeningitis.  Am J Med. 1971;  51 200-208
• 29 Kaplan J G, DeSouza T G, Farkash A et al.. Leptomeningeal metastases: comparison of clinical features and laboratory data of solid tumors, lymphomas and leukemias.  J Neurooncol. 1990;  9 225-229
• 30 Glantz M J, Cole B F, Glantz L et al.. Cerebrospinal fluid cytology in patients with cancer: how to minimize false negative results.  Cancer. 1998;  82 733-739
• 31 Freilich R J, Krol G, DeAngelis L M. Neuroimaging and cerebrospinal fluid cytology in the diagnosis of leptomeningeal metastasis.  Ann Neurol. 1995;  38 51-57
• 32 Collie D A, Brush J P, Lammie G A et al.. Imaging features of leptomeningeal metastases.  Clin Radiol. 1999;  54 765-771
• 33 Glantz M J, Cole B F, Recht L et al.. High dose intravenous methotrexate for patients with leptomeningeal carcinomatosis: is intrathecal chemotherapy necessary?.  J Clin Oncol. 1998;  16 1561-1567
• 34 Glantz M J, Hall W A, Cole B F et al.. Diagnosis, management, and survival of patients with leptomeningeal cancer based on cerebrospinal fluid-flow status.  Cancer. 1995;  75 2919-2931
• 35 Bokstein F, Lossos A, Lossos I S, Siegal T. Central nervous system relapse of systemic non-Hodgkin's lymphoma: results of treatment based on high-dose methotrexate combination chemotherapy.  Leuk Lymphoma. 2002;  43 587-593
• 36 Grossman S A, Finkelstein D M, Ruckdeschel J C et al.. Randomized prospective comparison of intraventricular methotrexate and thiotepa in patients with previously untreated neoplastic meningitis.  J Clin Oncol. 1993;  11 561-569
• 37 Glantz M J, LaFollette S, Jaeckle K A et al.. Randomized trial of a slow-release versus a standard formulation of cytarabine for the intrathecal treatment of lymphomatous meningitis.  J Clin Oncol. 1999;  17 3110-3116
• 38 Sullivan M P, Chen T, Dyment P G et al.. Equivalence of intrathecal chemotherapy and radiotherapy as central nervous system prophylaxis in children with acute lymphatic leukemia: a Pediatric Oncology Group study.  Blood. 1982;  60 948-958
• 39 Chua S L, Seymor J F, Streater J, Wolf M M, Januszewicz E H, Prince H M. Intrathecal chemotherapy alone is inadequate central nervous system prophylaxis in patients with intermediate-grade non-Hodgkin's lymphoma.  Leuk Lymphoma. 2002;  43 1783-1788
• 40 Skarin A T, Canellos G P, Rosenthal D S et al.. Improved prognosis of diffuse histiocytic and undifferentiated lymphoma by use of high dose methotrexate alternating with standard agents (M-BACOD).  J Clin Oncol. 1983;  1 91-98
• 41 Perez-Soler R, Smith T L, Cabinillas F. Central nervous system prophylaxis with combined intravenous and intrathecal methotrexate in diffuse lymphoma of aggressive histologic type.  Cancer. 1986;  57 971-977
• 42 Johnson G J, Oken M M, Anderson J R et al.. Central nervous system relapse in unfavourable-histology non-Hodgkin's lymphoma: is prophylaxis indicated?.  Lancet. 1984;  2 685-687
• 43 Freedman B. Equipoise and the ethics of clinical research.  N Engl J Med. 1987;  317 141-145